XBiotech (NASDAQ:XBIT) will collaborate with
non-profit BioBridge Global in an FDA program to collect and distribute
convalescent plasma from people who have recovered from COVID-19
infection.
The company has developed a clinical test that
BioBridge Global subsidiary QualTex Laboratories will use to identify
natural antibodies to SARS-CoV-2 in donated plasma.
South Texas Blood & Tissue Center, another
BioBridge subsidiary, will collect the plasma and will provide blood
samples to XBIT for use in developing a True Human antibody therapy for
the infection.
Shares up 23% after hours.
https://seekingalpha.com/news/3558392-xbiotech-up-23-after-hours-on-convalescent-plasma-program-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.